PhRMA names Duato new board chairman

WASHINGTON — The Pharmaceutical Research and Manufacturers of America have announced Monday that Joaquin Duato, Johnson & Johnson’s worldwide chairman, pharmaceuticals, would be succeeding George Scangos, the outgoing CEO of Biogen, as the organization’s board chairman. 

 

“I am pleased to welcome Joaquin Duato as PhRMA board chairman and thank George Scangos for his leadership,” PhRMA president and CEO Stephen Ubl said."Through sustained investment in research and development, biopharmaceutical researchers and scientists have gained a better understanding of diseases and a greater ability to harness new scientific advances. Joaquin's focus on our industry's role in transforming lives will be crucial as we work with all stakeholders to make the health care system better and more responsive to the needs of patients."

 

Duato has been in his role at J&J since January 2011 and has been at the company for 28 years, working across its pharmaceutical and medical device business segments, holding regional chairman roles and leading local market businesses in various countries and regions. 

 

"In the words of Dr. Paul Janssen, 'the patients are waiting,’” Duato said. "Medicines are the best  — and only — hope for treating and curing the most devastating diseases. At a time of extraordinary advances in medical discovery, I look forward to leading PhRMA and ensuring patients have access to the treatments of today and the cures of tomorrow."